日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis of five clinical trials from two decades of the German AIO study group

晚期胰腺癌全身化疗治疗过程中的变化:德国AIO研究组二十年来五项临床试验的汇总分析

Weiss, L; Fischer, L E; Heinemann, V; Gieseler, F; Hoehler, T; Mayerle, J; Quietzsch, D; Reinacher-Schick, A; Schenk, M; Seipelt, G; Siveke, J T; Stahl, M; Kaiser, U; Waldschmidt, D T; Dorman, K; Zhang, D; Westphalen, C B; Boeck, S; Haas, M

Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205

卡培他滨和奥沙利铂联合贝伐珠单抗和伊马替尼治疗转移性结直肠癌患者的I/II期临床试验:AIO KRK 0205

Hoehler, T; von Wichert, G; Schimanski, C; Kanzler, S; Moehler, M H; Hinke, A; Seufferlein, T; Siebler, J; Hochhaus, A; Arnold, D; Hallek, M; Hofheinz, R; Hacker, U T

Hepatitis B surface antigen presentation and HLA-DRB1*- lessons from twins and peptide binding studies.

乙型肝炎表面抗原呈递和 HLA-DRB1*——来自双胞胎和肽结合研究的启示

Kruger A, Adams P, Hammer J, Böcher W O, Schneider P M, Rittner C, Hoehler T